The first patients receive synthetic craniofacial bone implants, manufactured on Desktop Health 3D bioplotters

Desktop Health announced the first therapeutic procedures on patients using synthetic craniofacial bone grafts, developed and manufactured by Dimension Inx from Chicago, USA, using a 3D bioplotter. Dimension Inx is a regenerative therapy company that designs, develops and manufactures therapeutic products aimed at restoring tissue and organ function. The company has four 3D bioplotters produced by Desktop Health – two of them are used for research and development purposes, and another two for the production of CMFlex.

Dimension Inx received certification from the FDA in December last year to use CMFlex in therapeutic procedures. The solution is currently available to a limited number of key surgeons and will be fully launched in 2024.

“The first use cases of synthetic bone grafts not only demonstrate the spectrum of new possibilities offered by biomaterials, but also highlight the unique ability of our technology platform to rapidly create solutions that direct cell behavior to restore tissue and organ function. This is an important moment for us as we can demonstrate the value of therapies derived from the integration of biomaterials and 3D printing,” said Dr. Adam Jakus, Chief Technology Officer, Director of Technology Strategy and Co-Founder of Dimension Inx.

The first cases of jaw implants were performed by Dr. Derek Steinbacher, director of West River Surgery Center, former professor of plastic surgery and chief of oral and maxillofacial surgery at Yale New Haven Health, and Dr. Brian Farrell, DDS, MD, of the Carolina Center for Oral and Maxillofacial Surgery. Face. The procedures performed included surgical enlargement of the angle of the mandible and segmental osteotomy of the maxilla – i.e. surgery on the upper jaw. CMFlex has also been used in socket preservation surgery for future dental implant placement by Dr. Robert Bosack, DDS, Oral, Maxillofacial and Dental Implant Surgery.

Dr. Ramille Shah, CSO, head of research and development and co-founder of Dimension Inx, added: “We are thrilled with the interest we have already received from surgeons who recognize the importance of our solution and the ability to trim and shape the graft to fit the defect site.”


Comments are closed.

You may also like

More in Bioprinting